Maximizing cure for muscle-invasive bladder cancer: Integration of surgery and chemotherapy

European Urology

Volumn 59, Issue 6, 2011, Pages 978-984

  Feifer, Andrew H ^a   Taylor, Jennifer M ^a   Tarin, Tatum V ^a   Herr, Harry W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder cancer; Chemotherapy; Cystectomy; Multidisciplinary management

Indexed keywords

CISPLATIN; CREATININE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CREATININE CLEARANCE; CYSTECTOMY; DISTANT METASTASIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HUMAN; LYMPH NODE DISSECTION; MEDICAL LITERATURE; MICROMETASTASIS; MUCOSA INFLAMMATION; MUSCLE INVASIVE BLADDER CANCER; MUSCLE METASTASIS; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PELVIS LYMPH NODE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; ROBOTICS; SURGEON; THERAPY EFFECT; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; LYMPH NODE EXCISION; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 79955608021     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.01.014     Document Type: Review

References (62)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
3. M.F. Botteman, C.L. Pashos, A. Redaelli, B. Laskin, and R. Hauser The health economics of bladder cancer: a comprehensive review of the published literature Pharmacoeconomics 21 2003 1315 1330 (Pubitemid 38041357)
4. H.W. Herr, Z. Dotan, S.M. Donat, and D.F. Bajorin Defining optimal therapy for muscle invasive bladder cancer J Urol 177 2007 437 443 (Pubitemid 46075130)
5. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866 (Pubitemid 37025405)
6. G. Dalbagni, E. Genega, and M. Hashibe Cystectomy for bladder cancer: a contemporary series J Urol 165 2001 1111 1116 (Pubitemid 32210214)
7. S. Madersbacher, W. Hochreiter, and F. Burkhard Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy J Clin Oncol 21 2003 690 696 (Pubitemid 46621904)
8. P.U. Malmstrom, E. Rintala, R. Wahlqvist, P. Hellstrom, S. Hellsten, and E. Hannisdal Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group J Urol 155 1996 1903 1906 (Pubitemid 26144081)
9. Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 2003 1927 1934
10. C.N. Sternberg, A. Yagoda, and H.I. Scher Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse Cancer 64 1989 2448 2458 (Pubitemid 20014925)
11. P.K. Schultz, H.W. Herr, and Z.F. Zhang Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up J Clin Oncol 12 1994 1394 1401 (Pubitemid 24206237)
12. K.A. David, M.I. Milowsky, J. Ritchey, P.R. Carroll, and D.M. Nanus Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base J Urol 178 2007 451 454 (Pubitemid 47030482)
13. U. Fedeli, S.A. Fedewa, and E.M. Ward Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007 J Urol 185 2011 72 78
14. G.V. Raj, S. Karavadia, and B. Schlomer Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer Cancer 117 2011 276 282
15. B.J. Miles, A.S. Fairey, and M. Eliasziw Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline Can Urol Assoc J 4 2010 263 267
16. M.E. Nielsen, G.S. Palapattu, and P.I. Karakiewicz A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome BJU Int 100 2007 1015 1020 (Pubitemid 47537661)
17. R. Millikan, C. Dinney, and D. Swanson Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC J Clin Oncol 19 2001 4005 4013 (Pubitemid 32976686)
18. Ploeg M, Kiemeney LA, Smits GA, et al. Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol. In press. doi:10.1016/j.urolonc.2009.12.020.
19. S. McLaughlin, J. Shephard, E. Wallen, S. Maygarden, C.C. Carson, and R.S. Pruthi Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer Int Braz J Urol 33 2007 25 31 discussion 31-2
20. M.S. Soloway, A.E. Lopez, J. Patel, and Y. Lu Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy Cancer 73 1994 1926 1931 (Pubitemid 24101973)
21. S.M. Donat Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality J Natl Compr Canc Netw 7 2009 40 47
22. A. Dash, M.D. Galsky, and A.J. Vickers Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder Cancer 107 2006 506 513 (Pubitemid 44107210)
23. G. Sonpavde, and C.N. Sternberg Neoadjuvant systemic therapy for urological malignancies BJU Int 106 2010 6 22
24. H. Von der Maase, S.W. Hansen, and J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
25. M. Aristides, H. Von Der Maase, T. Roberts, A. Brown, A. Kielhorn, and S. Bhalla Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer Eur J Cancer Care (Engl) 14 2005 141 142 (Pubitemid 40655730)
26. M.D. Galsky, H.W. Herr, and D.E. Bajorin The integration of chemotherapy and surgery for bladder cancer J Natl Compr Canc Netw 3 2005 45 51 (Pubitemid 44265454)
27. B. Fisher, J. Dignam, and N. Wolmark Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer J Natl Cancer Inst 89 1997 1673 1682 (Pubitemid 27508191)
28. J.S. Mieog, J.A. van der Hage, and C.J. van de Velde Neoadjuvant chemotherapy for operable breast cancer Br J Surg 94 2007 1189 1200 (Pubitemid 47584766)
29. H.W. Herr, J.R. Faulkner, and H.B. Grossman Surgical factors influence bladder cancer outcomes: a cooperative group report J Clin Oncol 22 2004 2781 2789 (Pubitemid 41079895)
30. A. Dash, J.A. Pettus, and H.W. Herr A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience Cancer 113 2008 2471 2477
31. G. Sonpavde, B.H. Goldman, and V.O. Speights Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy Cancer 115 2009 4104 4109
32. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 202 206 discussion 205-6
33. International collaboration of trialists Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial Lancet 354 1999 533 540
34. Galsky MD, Hellerstedt SA, McKenney TE, et al. Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC). Abstract no. 276. Presented at: 2010 ASCO Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA, USA.
35. Messing EM, Ely B, Scosyrev E, et al. Do mixed histologic features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? Abstract no. 274. Presented at: 2010 ASCO Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA, USA.
36. D.J. Gallagher, and M.I. Milowsky Bladder cancer Curr Treat Options Oncol 10 2009 205 215
37. W.M. Stadler, and S.P. Lerner Perioperative chemotherapy in locally advanced bladder cancer Lancet 361 2003 1922 1923 (Pubitemid 36694575)
38. M.G. Kaag, R.L. O'Malley, and P. O'Malley Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy Eur Urol 58 2010 581 587
39. L. Dogliotti, G. Carteni, and S. Siena Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial Eur Urol 52 2007 134 141 (Pubitemid 46803003)
40. R. Petrioli, B. Frediani, and A. Manganelli Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study Cancer 77 1996 344 351
41. J. Bellmunt, A. Ribas, and N. Eres Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma Cancer 80 1997 1966 1972 (Pubitemid 27479792)
42. C.J. Weight, J.A. Garcia, and D.E. Hansel Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series Cancer 115 2009 792 799
43. Vale CL; Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2006:CD006018.
44. R.S. Svatek, S.F. Shariat, and R.E. Lasky The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder Clin Cancer Res 16 2010 4461 4467
45. T.B. Dorff, D. Tsao-Wei, G. Miranda, D.G. Skinner, J.P. Stein, and D.I. Quinn Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience World J Urol 27 2009 39 44
46. Sternberg CN. EORTC protocol 30994 summary. European Organization for Research and Treatment of Cancer Web site. http://www.eortc.be/protoc/details. asp?protocol=30994. Accessed October 25, 2010.
47. Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. Abstract LBA4518. Presented at: ASCO Annual Meeting; June 4-8, 2010; Chicago, IL, USA.
48. S.M. Donat, A. Shabsigh, and C. Savage Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience Eur Urol 55 2009 177 186
49. H.W. Herr Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer Eur Urol 54 2008 126 132
50. W.F. Whitmore Jr., and V.F. Marshall Radical total cystectomy for cancer of the bladder: 230 consecutive cases five years later J Urol 87 1962 853 868
51. V.F. Marshall, and W.F. Whitmore Jr. The present position of radical cystectomy in the surgical management of carcinoma of the urinary bladder J Urol 76 1956 387 391
52. N.B. Dhar, E.A. Klein, A.M. Reuther, G.N. Thalmann, S. Madersbacher, and U.E. Studer Outcome after radical cystectomy with limited or extended pelvic lymph node dissection J Urol 179 2008 873 878 discussion 878
53. H.W. Herr Extent of pelvic lymph node dissection during radical cystectomy: where and why! Eur Urol 57 2010 212 213
54. H. Herr, B. Konety, J. Stein, C.N. Sternberg, and D.P. Wood Jr. Optimizing outcomes at every stage of bladder cancer: do we practice it? Urol Oncol 27 2009 72 74
55. T.M. Koppie, A.J. Vickers, K. Vora, G. Dalbagni, and B.H. Bochner Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer 107 2006 2368 2374 (Pubitemid 44748519)
56. Z.A. Dotan, K. Kavanagh, and O. Yossepowitch Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival J Urol 178 2007 2308 2312
57. J.D. Birkmeyer, A.E. Siewers, and E.V. Finlayson Hospital volume and surgical mortality in the United States N Engl J Med 346 2002 1128 1137 (Pubitemid 34984604)
58. J.D. Birkmeyer, T.A. Stukel, A.E. Siewers, P.P. Goodney, D.E. Wennberg, and F.L. Lucas Surgeon volume and operative mortality in the United States N Engl J Med 349 2003 2117 2127 (Pubitemid 37464537)
59. J.A. Eastham Do high-volume hospitals and surgeons provide better care in urologic oncology? Urol Oncol 27 2009 417 421
60. N.J. Hellenthal, A. Hussain, and P.E. Andrews Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium J Urol 184 2010 87 91
61. V. Ficarra, O. Dalpiaz, N. Alrabi, G. Novara, A. Galfano, and W. Artibani Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma BJU Int 95 2005 786 790 (Pubitemid 40547207)
62. D.C. Chade, V.P. Laudone, B.H. Bochner, and R.O. Parra Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches J Urol 183 2010 862 869